Insulin-like growth factors (IGF) and IGF-binding proteins in the serum of patients with ovarian cancer and borderline and benign tumors


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Objective. To comparatively estimate the serum levels of insulin-like growth factors (IGF) 1 and 2 and IGF-bindingproteins (IGFBP) 1, 2, and 3 in patients with different ovarian neoplasms and to analyze their relationship to the clinical and morphological characteristics of ovarian cancer. Subject and methods. The serum levels of IGF-1, IGF-2, and IGFBP 1, 2, and 3 were estimated in 44primary patients with ovarian cancer, in 11 and 12 patients with borderline and benign ovarian tumors, respectively, by applying the Mediagnost direct enzyme immunoassay sets. A control group included 33 apparently healthy women. Results. The serum level of IGF-1 was significantly decreased and that of IGFBP-1 was increased in the patients with ovarian cancer versus all other groups. The blood content of IGFBP-2 was higher in the patients with cancer and borderline tumors as compared to the controls and patients with benign tumors. No relationship was found between the majority of examined indicators and the clinical and morphological characteristics of ovarian cancer; however, the level of IGFBP-2 was significantly increased with a higher FIGO grade and positively correlated with CA-125 levels. Conclusion. Serum IGF/IGFBP imbalance was detected in the patients with ovarian cancer. IGFBP-2 was shown to be a potential serological marker for ovarian cancer at 90% sensitivity and 90% specificity.

Texto integral

Acesso é fechado

Sobre autores

Elena Gershtein

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Email: esgershtein@gmail.com
professor, MD, Leading Researcher of Laboratory of Clinical Biochemistry

Emiliya Isaeva

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Email: dr.isaeva@inbox.ru
graduate student, Department of tumors of the female reproductive system

Dmitry Kushlinsky

Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: dnkushlinskiy@mail.ru
PhD, oncogynecologist, Department of combined and integrated treatment of gynecological diseases

Ekaterina Korotkova

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

PhD, junior scientific worker, Researcher of Laboratory of Clinical Biochemistry

Valeriya Ermilova

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

PhD, leading researcher of department of Pathological Anatomy of human tumors

Konstamtin Laktionov

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Professor, MD, Head of tumors of the female reproductive system

Leila Adamyan

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russia

Email: l_adamyan@oparina4.ru
MD, PhD, Professor, Academician of the Russian Academy of Medical Sciences, Head of the Department of Operative Gynecology

Bibliografia

  1. Герштейн Е.С., Короткова Е.А., Щербаков А.М., Пророков В.В., Головков Д.А., Кушлинский Н.Е. Матриксные металлопротеиназы 7 и 9 и их тканевые ингибиторы 1 и 4 типа в опухолях и плазме крови больных раком толстой кишки. Бюллетень экспериментальной биологии и медицины. 2007; 143(3): 438-41. [Gerstein E.S., Korotkova E.A., Shcherbakov A.M., Prorokov V.V., Golovkov D.A., Kushlinsky N.E. Matrix metalloproteinase 7 and 9 and their tissue inhibitors of type 1 and 4 in tumors and serum of patients with colon cancer. Bulletin of Experimental Biology and Medicine. 2007; 143 (3): 438-41.]
  2. Druckmann R., Rohr U.D. IGF-1 in gynaecology and obstetrics: update 2002. Maturitas. 2002; 41(Suppl. 1): S65-83.
  3. Brokaw J., Katsaros D., Wiley A., Lu L., Su D., Sochirca O. et al. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors. 2007; 25(5): 346-54.
  4. Huang G.S., Brouwer-Visser J., Ramirez M.J., Kim C.H., Hebert T.M., Lin J. et al. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin. Cancer Res. 2010; 16(11): 2999-3010.
  5. Sayer R.A., Lancaster J.M., Pittman J., Gray J., Whitaker R., Marks J.R., Berchuck A. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol. Oncol. 2005; 96(2): 355-61.
  6. Spentzos D., Cannistra S.A., Grail F., Levine D.A., Pillay K., Libermann T.A., Mantzoros C.S. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr. Relat. Cancer. 2007; 14(3): 781-90.
  7. Bruchim I., Werner H. Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin. Ther. Targets. 2013; 17(3): 307-20.
  8. Westin S.N., Herzog T.J., Coleman R.L. Investigational agents in development for the treatment of ovarian cancer. Invest. New Drugs. 2012; 31(1): 213-29.
  9. Beauchamp M.C., Yasmeen A., Knafo A., Gotlieb W.H. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J. Oncol. 2010; 2010: 257058.
  10. Maloney E.K., McLaughlin J.L., Dagdigian N.E., Garrett L.M., Connors K.M., Zhou X.M. et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 2003; 63(16): 5073-83.
  11. Shao M., Hollar S., Chambliss D., Schmitt J., Emerson R., Chelladurai B. et al. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. Mol. Cancer Ther. 2012; 11(7): 1576-86.
  12. Karp D.D., Poliak M.N., Cohen R.B., Eisenberg P.D., Haluska P., Yin D. et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J. Thorac. Oncol. 2009; 4(11): 1397-403.
  13. Ji Q.S., Mulvihill M.J., Rosenfeld-Franklin M., Cooke A., Feng L., Mak G. et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol. Cancer Ther. 2007; 6(8): 2158-67.
  14. Beauchamp M.C., Knafo A., Yasmeen A., Carboni J.M., Gottardis M.M., Pollak M.N., Gotlieb W.H. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecol. Oncol. 2009; 115(2): 193-8.
  15. Banerjee S., Kaye S.B. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin. Cancer Res. 2013; 19(5): 961-8.
  16. Tolcher A.W, Mita M., Meropol N.J., von Mehren M., Patnaik A., Padavic K. et al. Phase I pharmacokinetic and biologic correlative study of mapatu-mumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 2007; 25(11): 1390-5.
  17. Масляев А.В., Костылева О.И., Герштейн Е.С., Ермилова В.Д., Грицкевич М.В., Портной С.М. Инсулиноподобные факторы роста в сыворотке крови больных раком молочной железы. Вопросы биологической, медицинской и фармацевтической химии. 2012; 10: 16-20. [Maslyaev A.V. Kostyleva O.I., Gerstein E.S., Ermilova V.D., Gritskevich M.V., Portnoy S.M. Insulin-like growth factors in the serum of patients with breast cancer. Questions of biological, medical and pharmaceutical chemistry. 2012; 10: 16-20.]
  18. Короленкова Л.И., Герштейн Е.С., Кушлинский Д.Н., Ермилова В.Д., Дворова Е.К. Инсулиноподобные факторы роста сыворотки крови больных цервикальной интраэпителиальной гиперплазией и инвазивным раком шейки матки как перспективные маркеры прогрессии заболевания. Вопросы биологической, медицинской и фармацевтической химии. 2012; 10: 21-35. [Korolenkova L.I., Gerstein E.S., Kushlinsky D.N., Ermilova V.D., Dvorova E.K. Insulin-like growth factors in serum of the patients with cervical intraepithelial hyperplasia and invasive cervical cancer as promising markers of disease progression. Questions to biological, medical and pharmaceutical chemistry. 2012; 10: 21-35.]
  19. Waksmanski B., Dudkiewicz J., Kowalski T. Changes in insulin-like growth factor I, 17-b-estradiol, and progesterone in postmenopausal women with benign and malignant ovarian tumours. Med. Sci. Monit. 2001; 7(5): 919-23.
  20. Katsaros D., Yu H., Levesque M.A., Danese S., Genta F., Richiardi G. et al. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. Eur. J. Cancer. 2001; 37(4): 47885.
  21. Baron-Hay S., Boyle F., Ferrier A., Scott C. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin. Cancer Res. 2004; 10(5): 1796-806.
  22. Peeters P.H., Lukanova A., Alien N., Berrino F., Key T., Dossus L. et al. Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr. Relat. Cancer. 2007; 14(1): 81-90.
  23. Tworoger S.S., Lee I.M., Buring J.E., Pollak M.N., Hankinson S.E. Insulinlike growth factors and ovarian cancer risk: a nested case-control study in three cohorts. Cancer Epidemiol. Biomarkers Prev. 2007; 16(8): 1691-5.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2014